Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: new month, still volatile as sector equities rebound

February 1, 2021 5:02pm

Be ready, you never lose money by selling into highs – earnings’ LPS (loss-per-share) season is on its way

Pre-open indication results: 5 HITs and 5 MISS

Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investor profiting! Numbers based facts speak better then opinion as I see answers in numbers

Sector earnings LPS (loss-per-share) season is about to begin?

The Dow closed UP +229.29 points (+0.76%); the S&P closed UP +59.62 points (+1.61%) while the Nasdaq closed UP +332.70 points (+2.55%)

Henry’omics:

Indexes jumped on Monday, the first session of February, as “our” universe of RegMed/Stem/Cell and Gene therapy equities shook-off concerns about a speculative trading that had driven the market’s worst weekly sell-off since October.

RegMed Investors’ (RMi) pre-open: “a sign of returning support and a rebound?” … https://www.regmedinvestors.com/articles/11747

Pre-open indication results: 5 HITs <SELL: Bellicum Pharmaceuticals (BLCM -$0.42), Ionis Pharmaceuticals (IONS -$1.10); BUY: bluebird bio (BLUE +$1.19), Homology Medicine (FIXX +$0.30), Pluristem (PSTI +$0.47)> and 5 MISS < Maintaining SELL: Biostage (BSTG +$0.13 with 1,211 shares traded - market manipulation?), Vericel (VCEL +$3.10), Global Blood Therapeutics (GBT -$0.63), Sage Therapeutics (SAGE +$2.01), Precigen (PGEN -$0.03), >

Data Docket: The ISM PMI, a key gauge of manufacturing activity, came in at 58.7, lower than in December and weaker than economists had expected.

Sentiment and COVID-19 infections:

The U.S.’ vaccine distribution plans face another obstacle as a winter storm is dumping one to two feet of snow from Pennsylvania into New England through Tuesday. < National Weather Service>

Infection cases <Million>: never to forget …

Monday 26.18 M cases,
Monday’s death rate totaled 441,367 <Johns Hopkins University>

RegMed/Stem/Cell and Gene therapy’s 35 covered equities’ Advance/Decline (A/D) lines: progressions and regressions

Monday opened positive at 27/7 and 1 flat, stayed positive at the mid-day to 27/7 and 1 flat, closing positive at 22/11, 1 flat and 1 acquired;
Friday opened positive at 26/8 and 1 flat, stayed positive at the mid-day to 9/24 and 2 flats, closing negative at 12/22 and 1 acquired;

Key metrics:

Sector volume was LOW with 2 of the 22-upside having higher than the 3-month average volume with the increased volume of 2 of 11-downside having higher than the 3-month average volume;

Monday’s percentage (%) of the22 -upside were +0.16% (ADVM) to +26.10% (ATHX) while the 11-downside ranges from -0.01% (CRSP) to -9.03% (BLCM);

There are clear winners — and losers — heading into the 2nd month of 2021.

Jumping with share pricing momentum:

Ultragenyx (RARE), Fate Therapeutics (FATE), Regenxbio (RGNX), Vericel (VCEL), BioLife Solutions (BLFS) to name 5 of the 22 inclining of the 35 covered

Hammered in today’s market:

Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals (IONS), Global Blood Therapeutics (GBT), Bellicum Pharmaceuticals (BLCM), Brainstorm Cell Therapeutics (BCLI) to name 5 of the 11 declining of the 35 covered

Monday’s (10 of 22) incliners:

Ultragenyx (RARE +$7.04 after Friday’s -$2.01);
Vericel (VCEL +$3.10 after Friday’s +$0.17);
Fate Therapeutics (FATE +$2.53);
Sage Therapeutics (SAGE +$2.01 after Friday’s +$1.38);
Regenxbio (RGNX +$1.87);
BioLife Solutions (BLFS +$1.67);
Editas Medicine (EDIT +$1.54 after Friday’s +$0.22);
Intellia Therapeutics (NTLA +$1.53 after Friday’s -$1.35);
bluebird bio (BLUE +$1.19);
Chinook Therapeutics (KDNY +$1.18);

Monday’s (11 of 11) decliners:

Alnylam Pharmaceuticals (ALNY -$1.23 after Friday’s -$4.26);
Ionis Pharmaceuticals (IONS -$1.10 after Friday’s -$0.62);
Global Blood Therapeutics (GBT -$0.63 after Friday’s +$1.78);
Bellicum Pharmaceuticals (BLCM -$0.42 after Friday’s +$0.81);
Brainstorm Cell Therapeutics (BCLI -$0.33);
Voyager therapeutics (VYGR -$0.05);
MiMedx (MDXG -$0.05 after Friday’s +$0.57);
Caladrius BioSciences (CLBS -$0.04 after Friday’s +$0.08);
Solid Biosciences (SLDB -$0.03 after Friday’s +$0.15);
Precigen (PGEN -$0.03 after Friday's +$0.07);
CRISPR Therapeutics (CRSP -$0.02 after Friday’s -$1.72);

Closing 1 – ReNeuron (RENE.L) and 1 - Stemline Therapeutics (STML – acquired)

Stats:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Monday, the IBB closed up +1.28% and XBI closed up +4.41%
Friday, the IBB closed up +0.14% and XBI closed up +0.82%

The CBOE Volatility Index (VVIX: INDEX) tracked:

Monday was down -2.85 points or -8.61% at 30.24
Friday was up +2.88 points or +9.53% at 30.09

Upside volume:

Monday: 2 out of the 22-upside had higher than the 3-month average volume;
Friday: 2 out of the 12-upside had higher than the 3-month average volume;

Downside volume:

Monday: 2 out of the 11-downside had higher than the 3-month average volume;
Friday: 3 out of the 22-downside had higher than the 3-month average volume;

Percentage (%) movement/range statistics: a 360 degrees comparison of % and pricing

Monday’s percentage (%) of the22 -upside were +0.16% (ADVM) to +26.10% (ATHX) while the 11-downside ranges from -0.01% (CRSP) to -9.03% (BLCM);
Friday’s percentage (%) of the 12-upside were +0.36% (EDIT) to +21.09% (BLCM) while the 22-downside ranges from -0.25% (AGTC) to-4.20% (BCLI);

February, the 2^nd month of Q1 … a visual review identifies the range of sector volatility

Monday (2/1) closed positive with 22 advancers, 11 decliners, 1 flat and 1 acquired

The Bottom Line: The return of volatility has many adjusting their portfolios to account for the risks to short positions.

Concerns over stretched valuations, new coronavirus variants and rising COVID-19 cases are keeping all of us on edge about the market and sector pullbacks in addition to the dramatic increase in volatility in the near-term.

There is STILL a short-term tone in the sector – “our’ universe of RegMed, stem, cell and gene therapy equities.

Let’s NOT forget, it is a new tax year thus, a cut back of some (I say many) gains in the sector before the release of Q4 and FY20 “earnings” i.e., LPS (loss-per-share)!

Forewarned … earnings LPS (loss-per-share) season is coming quickly – my advice, trim and skim!!

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.